InfuSystem releases updated 2024 outlook: revenue ~$134.2M, Adj. EBITDA ~$26.5M

InfuSystem Holdings, Inc

2024 estimated net revenue of $134.2M (+6.7% YoY); Adj. EBITDA $26.5M (high-teens margin).
Recent distribution agreements: Smith+Nephew RENASYS EDGE NPWT system; exclusive U.S. ChemoMouthpiece with Sanara MedTech.
Patient Services revenue $77.3M (TTM 6/30/24); Device Solutions $52.1M; gross margins 64.9% and 29.4%.
Net leverage 1.53x; $40.5M total liquidity; $20M share repurchase program authorized.
Five consecutive years of record revenue; 12% revenue CAGR 2019-2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.